Journal: Biomolecules & Therapeutics

Article Title: Taurine Synthesis by 2-Aminoethanethiol Dioxygenase as a Vulnerable Metabolic Alteration in Pancreatic Cancer

doi: 10.4062/biomolther.2024.086

Figure Lengend Snippet: Inhibition of ADO mitigates pancreatic cancer cell (PANC-1) growth in vitro . (A) Relative expression of ADO in PANC-1 cells after control, ADO-KD1, and ADO-KD2 siRNA transfection (n=3). Two-sided Welch’s t-test was used. (B) Relative level of taurine in PANC-1 cells after control, ADO-KD1, and ADO-KD2 transfection (n=5). Two-sided Welch’s t-test was used. A.U.=arbitrary unit. (C) (Left) Cell proliferation of PANC-1 after control, ADO-KD1, and ADO-KD2 siRNA transfection was detected by CCK assay (n=8). (Right) Relative cell proliferation to day 0. Two-sided Welch’s t-test was used. O.D.=optical density. (D) Clonogenic assay of PANC-1 cells after control and ADO-KD1 siRNA transfection (20-day cultivation, n=3). (E) Expression of NF-κB (p65 and phosphorylated p65) and MEK (MEK1 and phosphorylated MEK1/2) proteins in PANC-1 cells after control and ADO-KD1 siRNA transfection, as detected by western blot assay. Data are presented as the mean ± SD. * p <0.05, ** p <0.01 and *** p <0.001.

Article Snippet: Western blot experiment was conducted using primary antibodies against ADO (16479-1-AP, Proteintech, Rosemont, IL, USA), β-actin (sc-47778, Santa Cruz), p65 (sc-8008, Santa Cruz), phospho-p65 (#3033, CST, Danvers, MA, USA), MEK1 (#9124, CST), phospho-MEK1 (Thr286) (#9127, CST), phospho-MEK1/2 (Ser221) (#2338, CST), ERK1/2 (#9102, CST), and phospho-ERK1/2 (#4377, CST).

Techniques: Inhibition, In Vitro, Expressing, Control, Transfection, Clonogenic Assay, Western Blot